Shares of Vaxart Inc (NASDAQ:VXRT) hit a new 52-week low during mid-day trading on Monday . The company traded as low as $0.85 and last traded at $0.88, with a volume of 18211 shares. The stock had previously closed at $0.88.
The company has a current ratio of 1.96, a quick ratio of 1.96 and a debt-to-equity ratio of 0.17.
Vaxart (NASDAQ:VXRT) last announced its quarterly earnings results on Wednesday, February 6th. The biotechnology company reported ($0.66) earnings per share (EPS) for the quarter. The business had revenue of $1.77 million for the quarter. Vaxart had a negative return on equity of 82.05% and a negative net margin of 441.12%.
In other news, Director Michael J. Finney bought 181,818 shares of the business’s stock in a transaction dated Thursday, April 11th. The shares were acquired at an average price of $1.10 per share, for a total transaction of $199,999.80. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Sean Tucker bought 27,273 shares of the business’s stock in a transaction dated Thursday, April 11th. The shares were purchased at an average price of $1.10 per share, for a total transaction of $30,000.30. The disclosure for this purchase can be found here. 7.30% of the stock is owned by insiders.
A hedge fund recently bought a new stake in Vaxart stock. Dimensional Fund Advisors LP bought a new position in shares of Vaxart Inc (NASDAQ:VXRT) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 17,616 shares of the biotechnology company’s stock, valued at approximately $33,000. Dimensional Fund Advisors LP owned approximately 0.25% of Vaxart as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 5.88% of the company’s stock.
About Vaxart (NASDAQ:VXRT)
Vaxart, Inc, a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus.
Featured Article: Range Trading
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.